Antisense oligonucleotide (AO)-mediated exon skipping is a promising new therapy for Duchenne muscular dystrophy (DMD), recently demonstrating proof of principle for restoring the absent dystrophin protein in DMD patients. However, the range of AO chemistries available for exon skipping is limited; effective systemic dystrophin protein restoration has yet to be demonstrated and will be required for disease modification in patients; and the current approach is mutation-specific, necessitating ...Expand abstract
- Publisher copy:
- Copyright date:
Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge.
If you are the owner of this record, you can report an update to it here: Report update to this record